Table 2 Inhibition performance of selected tumor cell lines by the compounds 9 and 10
From: Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties
Compd no. | Cell viability (100%), 20 µM, 48 h | ||
|---|---|---|---|
A549 | PC9 | H460 | |
9a | 95.90 | 52.03 | 47.20 |
9b | 92.60 | 104.86 | 98.64 |
9c | 9.48 | 13.91 | 32.97 |
9d | 82.37 | 105.15 | 69.71 |
9e | 9.14 | 24.05 | 30.94 |
9f | 33.47 | 8.80 | 39.20 |
9 g | 91.65 | 88.64 | 97.85 |
9 h | 77.55 | 71.96 | 52.87 |
9i | 17.41 | 18.95 | 8.52 |
9j | 87.42 | 85.93 | 92.89 |
9k | 83.48 | 23.40 | 18.72 |
9 L | 73.36 | 47.77 | 20.32 |
9 m | 65.08 | 63.65 | 62.63 |
9n | 67.60 | 59.44 | 24.58 |
9o | 78.59 | 94.56 | 87.72 |
9p | 10.85 | 2.11 | 5.63 |
9q | 54.85 | 18.17 | 17.63 |
9r | 90.73 | 98.55 | 117.07 |
9s | 82.07 | 65.73 | 48.37 |
9t | 7.32 | 4.56 | 3.27 |
9u | 64.09 | 43.88 | 31.00 |
9v | 54.06 | 47.42 | 38.13 |
9w | 57.94 | 55.21 | 30.63 |
9x | 69.21 | 78.11 | 108.05 |
9y | 85.43 | 79.67 | 94.78 |
9z | 91.32 | 73.07 | 55.57 |
10a | 87.40 | 103.57 | 82.32 |
10b | 87.18 | 96.85 | 55.00 |
10c | 68.05 | 50.54 | 41.79 |
10d | 89.00 | 83.17 | 77.21 |
10e | 96.13 | 49.85 | 28.88 |
10f | 82.22 | 61.10 | 32.43 |
10 g | 71.58 | 54.61 | 35.98 |
10 h | 77.72 | 66.77 | 28.10 |
DTG | 108.82 | 91.66 | 27.24 |